Summary The phenotype of peripheral blood lymphocytes of 27 renal cell carcinoma patients before and at the end of subcutaneously given rIL-2 therapy was determined by two colour flow cytometry. Therapy induced changes in peripheral blood leucocyte composition and phenotypes were comparable to those reported for intravenously given rIL-2. The present paper shows a correlation between the 'activation status' of the patient before therapy and eventual response.
The therapeutical effects of recombinant interleukin-2 (rIL-2) therapy look promising in the case of renal cell carcinoma (RCC) and melanoma (Rosenberg et al., 1987; West et al., 1987) .
Most of the interleukin-2 therapies so far, involved the intravenous administration of high dose rIL-2, causing severe side effects. In our clinic, rIL-2 was administered subcutaneously (s.c.) which avoided severe side effects, whereas clinical results were comparable to the ones involving intravenous (i.v.) administration of rIL-2 (Sleijfer et al., 1990; 1992) . The immunomodulatory effects of subcutaneously administered rIL-2 still remain to be investigated.
The present paper gives data on the 'activation status' of the main peripheral blood lymphocyte subpopulations (helper T cells, cytotoxic T cells and NK cells) in 27 RCC patients by determining the expression of the activation marker HLADr on these lymphocytes before and after s.c. rIL-2 therapy (day 35 and day 40).
Materials and methods
Patients and therapeutic protocol All patients (27; 16 male and 11 female) had evaluable metastatic renal cell carcinoma (RCC). Their average age was 59 (range 41-74). Patients participated in a phase II study of treatment with subcutaneous rIL-2 (Sleijfer et al., 1990; 1992) 'Activation status' of the subpopulations Table II shows that the absolute numbers of various subpopulations expressing HLA-Dr had increased during rIL-2 therapy. No correlation was found when data obtained at the end of the therapy were compared with each other. However, the six patients with remission showed significantly higher absolute and relative numbers of lymphocytes just before the first rIL-2 administration (Table III) than the patients with no remission (P<0.01; Wilcoxon test). In addition, they had significantly higher absolute amounts of CD8bright+HLA-Dr+ (P<0.01), CD4+HLA-Dr+ (P=0.01), and CD56+ HLA-Dr+ (P<0.02) cells than the patients who did not respond (SD, PD, see Table III Each time a new cycle of treatment was started, the abolute lymphocyte count decreased rapidly, whereas a quick increase (rebound lymphocytosis) was found when administration of rIL-2 was stopped between day 5-7 of each cycle. All patients showed an increase in the absolute eosinophil count in the peripheral blood. These results, obtained with subcutaneously applied rIL-2, extend the findings of others (Sondel et al., 1988 ) monitoring patients treated intravenously with rIL-2. So, the results might be taken as an indication that subcutaneously given rIL-2, despite its considerably lower toxicity as compared to intravenously given rIL-2, has an effect on the immune system comparable to i.v.
given rIL-2.
The NK population showed the highest increase in relative and absolute numbers. This is in agreement with the results reported for intravenously administered rIL-2 (Weil-Hillman et al., 1989; Ellis et al., 1988) , although the increase in the relative and absolute numbers of the NK population during s.c. administration was less pronounced. In addition, the relative number and absolute number of NK cells (CD56+) expressing HLA-Dr had increased significantly.
Until now, no good correlation between phenotypical changes in the periphal blood and response to rIL-2 therapy has been found (Favrot et al., 1990) . One study concerning i.v. administered rIL-2, however, showed a positive correlation between remission and lymphocytosis (West, 1989) .
The study presented here extends the number of possible parameters correlated with response. It appears that high numbers of lymphocytes and high numbers of cells expressing the activation marker HLA-Dr prior to therapy are a prognostically favorable parameter (Table III) . Interestingly, the two patients with complete remissions showed considerably higher numbers of CD8bright and CD56 positive cells expressing HLA-Dr. These high numbers of activated CD8bright cells might reflect a more immunogenic tumour in these patients. Summarising, the study presented here shows that subcutaneously administered rIL-2 induces immunological changes comparable to intravenously administered for each group ofpatients. dSignificantly higher than non-responders (P < 0.01); eSignificantly higher than non-responders (P < 0.02). Statistical significance was calculated using the Wilcoxon test (two-sided).
rIL-2. We have already shown that s.c., in contrast to i.v., administered rIL-2, induces no severe side effects, whereas clinical responses are comparable (Sleijfer et al., 1990; 1992) .
Most importantly, this report shows that the 'activation status' of the patient prior to therapy is related to the outcome of therapy.
